Showing results (201-210 of 236) with videos related to
Sort By:
Pageof 24
Cancers|September 23, 2022
Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse SettingMargarita Romeo, Marta Gil-Martín, Lydia Gaba, et al.Journal for Immunotherapy of Cancer|July 24, 2021
CX-072 (pacmilimab), a Probody <b></b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human studyAung Naing, Fiona Thistlethwaite, Elisabeth G E De Vries, et al.Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA TrialUrsula A Matulonis, Lydia Walder, Trine J Nøttrup, et al.Molecular Oncology|April 25, 2023
Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre networkNúria Mulet Margalef, Carmen Castillo, Miguel Mosteiro, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2014
Cysteamine (Cystagon®) adherence in patients with cystinosis in Spain: successful in children and a challenge in adolescents and adultsGema Ariceta, Enrique Lara, Juan A Camacho, et al.Gynecologic Oncology|September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancerDanny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.Journal of the American Heart Association|February 12, 2026
Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post-Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by KlothoSara Vázquez-Sánchez, Ana Blasco, Marina Polo-Salguero, et al.Cancers|November 25, 2023
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG SurveyHannah Woopen, Maren Keller, Dario Zocholl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.Pageof 24